Mobile Health and Wearable Devices for Diabetes Complication Management

Launched by SECOND XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Aug 11, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how using smart technology, like wearable devices and smartphones, can help people with Type 2 Diabetes manage and possibly prevent complications related to their condition. The study aims to test a computer program that uses information from health records, lab tests, and wearable devices to predict the risk of developing diabetes-related problems. It will also explore if combining this technology with personalized lifestyle support—like tracking diet and exercise—can improve health outcomes for participants.

People eligible to join are adults diagnosed with Type 2 Diabetes who are willing to use wearable devices and smartphone apps to help manage their condition. Participants will need to share detailed information about their lifestyle, including medical history, medications, diet, and exercise habits. The study will follow them for about three months to see how well this approach works. Those with serious health issues like advanced heart or liver problems, pregnancy, mental illness, or who are on insulin therapy won’t be able to participate. Overall, this trial hopes to offer new, technology-based ways to better support people living with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed diagnosis of Type 2 Diabetes;
• • 2. Aged ≥ 18 years;
• • 3. Able to accept the diabetes management model with AI-assisted management and wearable device monitoring;
• • 4. Able to provide complete lifestyle records, including medical history, medication status, diet, exercise, etc.;
• • 5. Fully understand the purpose, nature, and methods of the study, voluntarily participate in this study, accept a 3-month follow-up, and sign the informed consent form.
• Exclusion Criteria:
• • 1. Having severe mental illness or language barriers;
• • 2. Suffering from malignant tumors;
• • 3. Pregnant or lactating women;
• • 4. Suspected active infections (such as active pulmonary tuberculosis, pneumonia, etc.);
• • 5. Severe hepatic and renal insufficiency (alanine transaminase and/or aspartate transaminase \> 3 times the upper limit of normal; estimated glomerular filtration rate \< 15 mL/min/1.73 m²);
• • 6. A history of definite major adverse cardiovascular events and/or revascularization and/or intravenous thrombolysis and/or endovascular thrombectomy;
• • 7. Uncontrolled hyperthyroidism or hypothyroidism, pituitary-adrenal dysfunction, or other endocrine diseases;
• • 8. Alcoholism or drug addiction;
• • 9. Receiving insulin therapy;
• • 10. Unable to accept new comprehensive intervention technologies for various reasons (such as personal beliefs, economic factors, etc.).